Anthrax is a highly infectious disease caused by Bacillus anthracis, and aerosolization of the dried bacterial spores is a major biological warfare and bioterrorism threat. Two plasmid-encoded anthrax toxins are essential for bacterial virulence. Edema toxin (EdTx) is comprised of edema factor (EF) and protective antigen (PA), while lethal toxin (LeTx) is a molecular complex of lethal factor (LF) and PA. EF is a secreted calmodulin-dependent adenylyl cyclase enzyme that causes tissue edema, and LF is a uniquely selective Zn++-metalloprotease that inactivates important cell-signaling enzymes (mitogen-activated protein kinase kinases [MAPKKs]) in mammalian cells. PA is the receptor-binding component, which delivers the catalytic components into the cytosol of cells. Our hypothesis is that novel drugs (specific inhibitors of anthrax toxins) can be prepared to reduce the virulence of these bacteria for humans/animals and provide a new therapeutic adjunct to antibiotic therapy and vaccination. The proposal is based on our extensive preliminary studies of new heterocyclic compounds (e.g., prostaglandin E2-L-histidine) that specifically block the adenylyl cyclase activity of EF, and knowledge of metalloprotease inhibitors that block LF activity. Objective 1 will evaluate the capacity o PGE2-L-histidine and PGE2-imidazole to reduce adenylyl cyclase activity of the EF toxin component using an in vitro enzyme assay. We will then use these data to design other inhibitors and dock them on the known crystal structures of EF and other adenylyl cyclases. Objective 2 will identify and characterize inhibitors that block the Zn++-metalloprotease activity of LF, and we will use these data in 3D-Quantitative structure activity relationship (QSAR) computations to optimize the enzyme inhibitors. Objective 3 will test the effectiveness of the EF and LF inhibitors in protecting cultured cells and mice challenged with toxins or B. anthracis. Objective 4 will evaluate the pharmacologic and toxicologic properties of these toxin inhibitors in experimental animals and establish their relative safety. Development of new drugs for anthrax by combining the inhibitors of EF and LF should reduce the virulence of B. anthracis, increase the efficacy of antibiotics, promote killing of the bacteria by phagocytes, and enhance vaccine-induced immunity.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Project--Cooperative Agreements (U01)
Project #
1U01AI053858-01
Application #
6576997
Study Section
Special Emphasis Panel (ZAI1-ALR-M (S1))
Program Officer
Baker, Phillip J
Project Start
2002-09-30
Project End
2007-07-31
Budget Start
2002-09-30
Budget End
2003-07-31
Support Year
1
Fiscal Year
2002
Total Cost
$370,917
Indirect Cost
Name
University of Texas Medical Br Galveston
Department
Microbiology/Immun/Virology
Type
Schools of Medicine
DUNS #
041367053
City
Galveston
State
TX
Country
United States
Zip Code
77555
Schein, Catherine H; Chen, Deliang; Ma, Lili et al. (2012) Pharmacophore selection and redesign of non-nucleotide inhibitors of anthrax edema factor. Toxins (Basel) 4:1288-300
Chen, Deliang; Ma, Lili; Kanalas, John J et al. (2012) Structure-based redesign of an edema toxin inhibitor. Bioorg Med Chem 20:368-76
Chatuev, B M; Peterson, J W (2010) Analysis of the sporicidal activity of chlorine dioxide disinfectant against Bacillus anthracis (Sterne strain). J Hosp Infect 74:178-83
Moen, Scott T; Blumentritt, Carla A; Slater, Terry M et al. (2010) Testing the efficacy and toxicity of adenylyl cyclase inhibitors against enteric pathogens using in vitro and in vivo models of infection. Infect Immun 78:1740-9
Evans, Scott E; Scott, Brenton L; Clement, Cecilia G et al. (2010) Stimulated innate resistance of lung epithelium protects mice broadly against bacteria and fungi. Am J Respir Cell Mol Biol 42:40-50
Moen, Scott T; Yeager, Linsey A; Lawrence, William S et al. (2008) Transcriptional profiling of murine organ genes in response to infection with Bacillus anthracis Ames spores. Microb Pathog 44:293-310
Chen, Deliang; Misra, Milind; Sower, Laurie et al. (2008) Novel inhibitors of anthrax edema factor. Bioorg Med Chem 16:7225-33
Peterson, Johnny W; Comer, Jason E; Baze, Wallace B et al. (2007) Human monoclonal antibody AVP-21D9 to protective antigen reduces dissemination of the Bacillus anthracis Ames strain from the lungs in a rabbit model. Infect Immun 75:3414-24
Negi, Surendra S; Schein, Catherine H; Oezguen, Numan et al. (2007) InterProSurf: a web server for predicting interacting sites on protein surfaces. Bioinformatics 23:3397-9
Chen, Deliang; Menche, Gerd; Power, Trevor D et al. (2007) Accounting for ligand-bound metal ions in docking small molecules on adenylyl cyclase toxins. Proteins 67:593-605

Showing the most recent 10 out of 16 publications